Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
6.59
-0.09 (-1.35%)
Aug 28, 2026, 4:00 PM EDT - Market closed
Gyre Therapeutics Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Gyre Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $18.67. The average 1-year stock price forecast is 183.31% higher than the current stock price, while the lowest is $18 (+173.14%) and the highest is $20 (+203.49%).
Price Target: $18.67 (+183.31%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Gyre Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Mar '26 | May '26 | Jun '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Noble Financial | Noble Financial | Buy Reiterates $20 | Buy | Reiterates | $20 | +203.49% | Aug 10, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $18 | Buy | Reiterates | $18 | +173.14% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
109.50M
from 116.59M
Decreased by -6.08%
Revenue Next Year
139.60M
from 109.50M
Increased by 27.49%
EPS This Year
-0.02
from 0.18
EPS Next Year
0.06
from -0.02
EPS and Forward PE are based on non-GAAP adjusted numbers.